iBio (IBIO) – Investment Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of iBio (NASDAQ: IBIO) recently:

• 12/29/2025 – iBio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – iBio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/18/2025 – iBio was upgraded by analysts at Lifesci Capital to a “strong-buy” rating.
• 12/15/2025 – iBio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – iBio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – iBio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – iBio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – iBio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/16/2025 – iBio was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating.
• 11/11/2025 – iBio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.